Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange

Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange

Nanjing Frontier Biotechnologies was approved to stage a $285 million IPO on the Shanghai STAR Exchange. Frontier has a China approved treatment for HIV, and it is developing another HIV treatment that it in-licensed from the Rockefeller...

Read more
Bio-Thera Starts China Trials of a Third Arthritis Biosimilar

Bio-Thera Starts China Trials of a Third Arthritis Biosimilar

Bio-Thera Solutions of Guangzhou has begun a China Phase I trial to examine the pharmacokinetics and safety of its BAT2506, a proposed biosimilar to Simponi® (golimumab), a Janssen treatment for arthritis/ulcerative colitis. The comparison trial...

Read more
Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

INVICTUS Achieved Primary Endpoint, Ripretinib Significantly Improved Progression Free Survival (PFS) Versus Placebo in Patients with Fourth-line and Fourth-line Plus GIST Median PFS for Ripretinib of 6.3 Months Versus Placebo of 1.0 Month...

Read more
Aslan Presents Progress Update on its Three Clinical Candidates

Aslan Presents Progress Update on its Three Clinical Candidates

Aslan Pharma of Singapore provided an update on the progress of its three clinical-stage oncology and immunology candidates: • The company signed up K-MASTER to run a 400 patient South Korean Phase Ib/II trial of its lead drug, varlitinib, in...

Read more
DelMar Reports Positive Phase II Data from China Trial of GBM Treatment

DelMar Reports Positive Phase II Data from China Trial of GBM Treatment

DelMar Pharma of Vancouver and Menlo Park reported early results from its China Phase II trial of VAL-083 as a first line treatment for glioblastoma multiforme. VAL-083 is being administered along with radiation to patients with newly-diagnosed...

Read more
Ascletis Opens Clinical Development Shanghai Center

Ascletis Opens Clinical Development Shanghai Center

Ascletis Pharma Inc.(1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today the opening of its...

Read more
Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China

Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China

Ligand Pharmaceuticals Inc. (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, the...

Read more
Shanghai’s Stemirna Raises $14 Million for RNA Drug Development

Shanghai’s Stemirna Raises $14 Million for RNA Drug Development

Stemirna Therapeutics, a Shanghai RNA biopharma, raised nearly $14 million in a Series A financing. Founded in 2016 by a group of returning PhDs from MD Anderson Cancer Center in Houston, the company uses its proprietary Core Shell Structure...

Read more
Vapo Health Completes Series A Round for Medical Device Business

Vapo Health Completes Series A Round for Medical Device Business

Vapo Health, a China medical device company specializing in nebulizers, completed a Series A financing led by CCB International. Although the specific amount was not disclosed, it was reported to be in the “millions of dollars” range...

Read more
Zai Lab Granted Expedited China Review for Brain Cancer Medical Device

Zai Lab Granted Expedited China Review for Brain Cancer Medical Device

Shanghai’s Zai Lab announced its electric field treatment for cancer, Tumor Treating Fields, was designated an Innovative Medical Device in China, which accelerates the approval process. Zai in-licensed greater China rights to the product...

Read more
Corindus Vascular Robotics Announces Definitive Agreement to Be Acquired by Siemens Healthineers

Corindus Vascular Robotics Announces Definitive Agreement to Be Acquired by Siemens Healthineers

Corindus Stockholders to Receive $4.28 Per Share All-Cash Transaction Valued at Approximately $1.1 Billion Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has entered...

Read more
China News Weekly 122 – Trump ratchets up US-China trade war with new  tariffs

China News Weekly 122 – Trump ratchets up US-China trade war with new tariffs

Click here to find more details This is NAI’s new China News Weekly. We will be covering the latest Chinese foreign investment trends every week. To continue to receive our China News Weekly, please click the button below to subscribe.

Read more
Do NOT follow this link or you will be banned from the site!